Selim Benbadis, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,574,978 of the $2,092,223 with a category attached, or 75.3%. It is spread thinly across 27 manufacturers, the largest accounting for just 17.6%. Among neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,061 payments — averaging $683.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$369K
- UCB, Inc.$365K
- Neurelis, Inc.$282K
- Jazz Pharmaceuticals Inc.$222K
- Eisai Inc.$218K
- Greenwich Biosciences, Inc.$199K
- plus $436K from 21 others
Across 237 payments — averaging $4264.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$251K
- Jazz Pharmaceuticals Inc.$228K
- Biogen$146K
- Greenwich Biosciences, Inc.$99K
- Takeda Pharmaceuticals U.S.A., Inc.$75K
- UCB SA$51K
- plus $160K from 8 others
What the payments were for
- Consulting fees$178,3989%
- Speaking & faculty fees$1,574,97875%
- Travel & lodging$280,56213%
- Food & beverage$58,2853%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 501 | $369,163 |
| UCB, Inc. | 558 | $365,425 |
| Neurelis, Inc. | 411 | $282,186 |
| Jazz Pharmaceuticals Inc. | 285 | $221,954 |
| Eisai Inc. | 354 | $218,239 |
| Greenwich Biosciences, Inc. | 282 | $199,181 |
| Livanova USA, Inc. | 320 | $152,021 |
| Catalyst Pharmaceuticals, Inc. | 94 | $97,026 |
| Sunovion Pharmaceuticals Inc. | 111 | $85,127 |
| GW Pharma Limited | 10 | $27,286 |
| Sumitomo Pharma America, Inc. | 36 | $20,970 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $18,998 |
| UCB SA | 4 | $7,772 |
| Aquestive Therapeutics, Inc. | 8 | $7,650 |
| Acadia Pharmaceuticals Inc | 4 | $4,036 |
| Biogen | 3 | $2,727 |
| UCB GmbH | 1 | $2,625 |
| Aucta Pharmaceuticals, Inc. | 6 | $2,598 |
| Ceribell, Inc. | 5 | $2,198 |
| Otter Pharmaceuticals, LLC | 1 | $1,761 |
| Neuropace, Inc. | 28 | $1,495 |
| Medtronic(2 entities) | 14 | $1,160 |
| Immedica Pharma US, Inc. | 3 | $311 |
| Zogenix Inc. | 1 | $123 |
| Biocodex, Inc. | 2 | $116 |
| Monteris Medical Corporation | 1 | $53 |
| Spark Therapeutics, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$434,151
- Fintepla$363,310
- XCOPRI$321,806
- Fycompa$300,815
- VALTOCO$254,020
- APTIOM$104,574
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$79,993
- VNS Therapy$54,728
- Cenobamate$38,551
- VNS - Sentiva$11,766
- SYMPAZAN$7,881
- Dayvigo$4,800
- DAYBUE$4,008
- Motpoly XR$2,500
- ACTIVA$820
- RNS Neurostimulator Kit$778
- Ceribell Rapid Response EEG$400
- ZTALMY$287
- RNS System$247
- POCKET EEG DEVICE$200
How this compares
$2,092,223 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 308 | $1,231,946 |
| SabrilVigabatrin | 13 | $435,748 |
| XcopriCenobamate | 201 | $298,159 |
| FinteplaFenfluramine Hcl | 16 | $296,111 |
| FycompaPerampanel | 129 | $193,362 |
| VimpatLacosamide | 111 | $149,231 |
| AptiomEslicarbazepine Acetate | 40 | $113,701 |
| LamictalLamotrigine | 66 | $113,426 |
| BriviactBrivaracetam | 56 | $101,385 |
| OnfiClobazam | 27 | $89,389 |
| ValtocoDiazepam | 52 | $87,448 |
| Rufinamide | 79 | $82,523 |
| KeppraLevetiracetam | 19 | $66,315 |
| Clobazam | 236 | $63,024 |
| Lacosamide | 394 | $47,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Vimpat, Briviact, Nayzilam | $365,425 | $562,143204 claims |
| SK Life Science, Inc.Xcopri | $369,163 | $298,159201 claims |
| Eisai Inc.Fycompa | $218,239 | $193,362129 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $85,127 | $113,70140 claims |
| Neurelis, Inc.Valtoco | $282,186 | $87,44852 claims |
| UCB SAKeppra | $7,772 | $66,31519 claims |
| Aquestive Therapeutics, Inc.Sympazan | $7,650 | $45,87612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.
Other neurology in Tampa
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Mark CascioneTampa$1.2M
- Tuan VuTampa$1M
- Katherine StandleyTampa$735K
- Susan SteenTampa$341K
- Rossitza ChichkovaTampa$294K
- Brody HenkelTampa$262K
- Jennifer JainTampa$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.